吉非替尼一线治疗晚期肺腺癌的临床观察  

Clinical Obeservations of Gefitinib in first-line treatment of Advanced Adenocarcinoma of Lung

作　　者：吕江清[1] 盛青[1] 张贤兰[1] 马志明[1] 苏珊[1] 苏宁[1] 

机构地区：[1]广州市胸科医院,广东广州510095

出　　处：《临床肺科杂志》2012年第3期503-504,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨吉非替尼一线治疗晚期肺腺癌的疗效及不良反应。方法选择住院及门诊确诊肺腺癌Ⅲb或Ⅳ期17例,每天一次口服吉非替尼250 mg,直至出现PD为止,根据WHO标准评价其疗效及毒性不良反应。结果 17例中1例达到完全缓解(CR),8例部分缓解(PR),3例病情稳定(SD),5例病情进展(PD),总有效率为52.9%,疾病控制率(PR+CR+SD)为70.6%。结论吉非替尼对于晚期非小细胞肺腺癌具有较好的疗效和耐受性。Objective To investigate the treatment effect and adverse reactions of gefitinib in first-line treatment of advanced adenocarcinoma of lung. Methods 17 inpatients and outpatients with diagnosed lung cancer Ⅲb or Ⅳ stage were selected, they orally took gefitinib 250 mg once a day until the emergence of PD, and the treatment effect and the toxicity adverse reaction of there were evaluated according to WHO criteria. Result One of 17 cases achieved complete remission （ CR）, 8 cases achieved partial remission （ PR）, 3 ca- ses achieved stable disease condition （SD）, 5 cases achieved disease progression （PD）, the total effective rate was 52.9%, and disease control rate （ PR ＋ CR ＋ SD） was 70. 6%. The most common adverse events were 1 to 2 degrees of skin rash and diarrhea, and no case retreated due to adverse reaction. Conclusion Gefitinib has better treatment effect and for tolerability for advanced non - small cell lung cancer.

关 键 词：吉非替尼 分子靶向治疗 非小细胞肺癌 腺癌 

分 类 号：R734.2[医药卫生—肿瘤]